Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2016-003083-39
    Sponsor's Protocol Code Number:20140444
    National Competent Authority:Belgium - FPS Health-DGM
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2016-11-24
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedBelgium - FPS Health-DGM
    A.2EudraCT number2016-003083-39
    A.3Full title of the trial
    A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Study to assess the safety and efficacy of denosumab vs. placebo in children with glucocorticoid-induced osteoporosis
    A.4.1Sponsor's protocol code number20140444
    A.7Trial is part of a Paediatric Investigation Plan Yes
    A.8EMA Decision number of Paediatric Investigation PlanP/058/2016
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAmgen Inc
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAmgen Inc
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAmgen N.V.
    B.5.2Functional name of contact pointMedical Information
    B.5.3 Address:
    B.5.3.1Street AddressTelecomlaan 5-7
    B.5.3.2Town/ cityDiegem
    B.5.3.3Post codeB-1831
    B.5.3.4CountryBelgium
    B.5.4Telephone number+322775 27 11
    B.5.6E-mailmedinfo-belux@amgen.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name XGEVA
    D.2.1.1.2Name of the Marketing Authorisation holderAmgen Europe B.V.
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameDenosumab
    D.3.2Product code AMG 162
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNdenosumab
    D.3.9.1CAS number 615258-40-7
    D.3.9.2Current sponsor codeAMG 162
    D.3.9.3Other descriptive nameDENOSUMAB
    D.3.9.4EV Substance CodeSUB29173
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number70
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for injection
    D.8.4Route of administration of the placeboSubcutaneous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Glucocorticoid-induced Osteoporosis
    E.1.1.1Medical condition in easily understood language
    Osteoporosis caused by taking glucocorticoids
    E.1.1.2Therapeutic area Diseases [C] - Musculoskeletal Diseases [C05]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10031287
    E.1.2Term Osteoporosis steroid-induced
    E.1.2System Organ Class 100000004859
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the effect of denosumab on lumbar spine bone mineral density (BMD) Z-score as assessed by dual-energy X-ray absorptiometry (DXA) at 12 months in
    children 5 to 17 years of age with glucocorticoid (GC)-induced osteoporosis (GiOP).
    E.2.2Secondary objectives of the trial
    To evaluate the effect of denosumab in children 5 to 17 years of age with GiOP with respect to:
    • Change in lumbar spine BMD Z-score as assessed by DXA from baseline to 6, 18, 24, and 36 months
    • Change in proximal femur BMD Z-score as assessed by DXA from baseline to 6, 12, 18, 24, and 36 months
    • Incidence of X-ray confirmed long-bone fractures and new and worsening vertebral fractures from pretreatment to posttreatment at 12, 24, and 36 months
    • Incidence of improving vertebral fractures from pretreatment to posttreatment at 12, 24, and 36 months (overall, among subjects with clinical fracture reduction, and among subjects with clinical fracture increase)
    • Incidence of pretreatment compared with posttreatment vertebral and nonvertebral fractures at 12, 24, and 36 months
    • Change in Childhood Health Questionnaire – Parent Form-50 (CHQ-PF-50) Physical Summary Score at 12, 24, and 36 months

    [For complete list of secondary objectives, please refer to the protocol]
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    PK/bone turnover markers (BTM) substudy of approximately 100 subjects
    to
    - determine serum concentration of denosumab at day 30 and month 3
    - evaluate changes observed in bone turnover markers (bone-specific alkaline phosphatase [BSAP], serum type I collagen C-telopeptide [sCTX]) at day 30 and month 3
    E.3Principal inclusion criteria
    - Subject’s legally acceptable representative has provided informed consent when the subject is legally too young to provide informed consent and the subject has provided assent based on local regulations and/or guidelines prior to any study-specific activities/procedures being initiated.
    • Male or female subjects, age 5 to 17 years, inclusive, at the time of informed consent
    • Clinical diagnosis of GiOP as defined by the following (and consistent with the International Society for Clinical Densitometry definition of osteoporosis in children and adolescents)
    − A confirmed diagnosis of non-malignant condition(s) requiring treatment with systemic GC (including, but not limited to, chronic rheumatologic, gastrointestinal, neurologic, respiratory, and/or nephrological conditions)
    o Subjects who are on systemic GC only as replacement therapy for adrenal insufficiency are not eligible for the study
    − Treatment with systemic GC (intravenous or oral) of any duration for the underlying non-malignant condition(s) within the 12 months prior to screening: Prepubertal children should be expected to require significant GC use during
    the study, per investigator opinion.
    − Evidence of at least 1 vertebral compression fracture of Genant Grade 1 or higher, as assessed by the central imaging vendor on lateral spine X-rays performed at screening or within 2 months prior to screening; OR, in the absence of vertebral compression fractures, presence of both clinically significant fracture history (ie, ≥ 2 long-bone fractures by age 10 years or ≥ 3 long-bone fractures at any age up to 17 years) and lumbar spine BMD Z-score ≤ -2.0, as assessed by the central imaging vendor
    E.4Principal exclusion criteria
    Current hyperthyroidism (unless well controlled on stable antithyroid therapy)
    • Current clinical hypothyroidism (unless well controlled on stable thyroid replacement therapy)
    • History of hyperparathyroidism
    • Current hypoparathyroidism
    • Any causes of primary or secondary osteoporosis (other than GC use), or previous exposure to non-GC medications, which the investigator considers to have been a major factor contributing to the patient’s fracture(s)
    • Current adrenal insufficiency as the sole indication for GC therapy
    • Duchenne muscular dystrophy with symptomatic cardiac abnormality
    • Current malabsorption
    • Known intolerance to calcium or vitamin D supplements
    • Active infection or history of infections, defined as follows:
    − Any active infection for which systemic anti-infectives were used within 4 weeks prior to screening
    − Serious infection, defined as requiring hospitalization or intravenous anti-infectives within 8 weeks prior to screening
    - Recurrent or chronic infection or other active infection that, in the opinion of the investigator, might compromise the safety of the subject
    - Rodding surgery within 5 months prior to screening or not yet healed
    • Anticipated major skeletal surgery within the next 12 months from day 1
    • Planned orthopedic surgery that, in the opinion of the investigator, would require missing any dose of investigational product in year 1 or 2 or more doses thereafter
    • History of rare hereditary problems of fructose intolerance
    • History of long QT syndrome
    • History of alcohol or drug abuse
    • History or evidence of any other clinically significant disorder, condition, or disease that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion
    • Serum albumin-corrected calcium < LLN or > 10% above upper limit of normal (ULN) at screening
    • Serum vitamin D < 20 ng/mL at screening
    • Serum phosphorus < LLN at screening
    • Aspartate aminotransferase and/or alanine aminotransferase > 1.5 x ULN (or > 5 x ULN in subjects with dystrophinopathies at screening
    In subjects with dystrophinopathies, AST or ALT elevation > 5 x ULN may not be exclusionary if
    o It is associated with serum creatine phosphokinase (CPK) elevation
    AND
    o Serum total bilirubin, alkaline phosphatase , gamma-glutamyltransferase, and prothrombin time/international normalized ratio are < ULN, and serum albumin is > LLN
    - There are no symptoms or signs of hepatic inflammation,
    • Serum total bilirubin > 1.5 x ULN at screening
    • Positive blood screen for human immunodeficiency virus (HIV)-1 or -2 antibody
    • Positive blood screen for hepatitis B surface antigen or hepatitis C antibody
    • Estimated glomerular filtration rate < 60 mL/min/1.73 m2 at screening
    • Less than 2 evaluable vertebrae by DXA evaluation in the region of interest L1-L4,
    • Prior treatment for bone disease with any of the following at any time:
    − Denosumab
    − Strontium
    − Fluoride
    • Recent Bisphosphonate (BP) treatment, according to the following guidelines:
    − Zoledronic acid (ZA) within 6 months prior to screening
    − Oral BP or intravenous BP if the first dose of investigational product
    would be before their next scheduled BP dose
    • Administration of any of the following treatment within 3 months prior to screening:
    − Growth hormone
    − Calcitonin
    − Cathepsin K inhibitor
    − Other bone active drugs including anti-convulsants and heparin
    − Chronic systemic ketoconazole, androgens, cinacalcet, aluminum, lithium, protease inhibitors, gonadotropin releasing hormone agonists
    • Initiation of any of the following biologic agents within 4 weeks prior to screening:
    − Anti-alpha 4 integrin antibody
    − Anti-CD4/CD8 T-cells
    − Anti-IL-12/IL-23
    − CTLA4 inhibitor
    − IL1 receptor antagonist
    − IL6 inhibitor
    − Monoclonal antibody to CD20
    − Tumor necrosis factor antagonist
    • Current treatment with > 1 biologic agent for underlying inflammatory disease
    • Currently pregnant or planning a pregnancy during the study and for an additional 5 months after the last dose of investigational product
    • Currently breastfeeding or planning on breastfeeding during the study and for an additional 5 months after the last dose of investigational product
    • For sexually active girls: refusal to use highly effective methods of contraception and to continue this practice for 5 months after the last injection of investigational product
    • Subject likely to not be available to complete all protocol-required study visits or procedures
    • Subject’s parent or legal representative has any kind of disorder that, in the opinion of the investigator, may compromise the ability to give written parental permission for informed consent
    • Currently receiving treatment in another investigational device or drug study, or< 30 days since ending treatment on another investigational device or drug study(ies).
    E.5 End points
    E.5.1Primary end point(s)
    Change from baseline in lumbar spine BMD Z-score as assessed by DXA at
    12 months
    E.5.1.1Timepoint(s) of evaluation of this end point
    at 12 months
    E.5.2Secondary end point(s)
    • Change from baseline in lumbar spine BMD Z-score as assessed by DXA at 6, 18, 24,
    and 36 months
    • Change from baseline in proximal femur BMD Z-score as assessed by DXA at 6, 12, 18, 24, and 36 months
    • Subject incidence of X-ray confirmed long-bone fractures and new and worsening vertebral fractures at 12, 24, and 36 months compared to pre-treatment
    • Subject incidence of improving vertebral fractures at 12, 24, and 36 months compared to pretreatment (overall, among subjects with clinical fracture reduction, and among subjects with clinical fracture increase)
    • Subject incidence of vertebral and nonvertebral fractures at 12, 24, and 36 months compared to pretreatment
    • Change from baseline in CHQ-PF-50 Physical Summary Score at 12, 24, and 36 months
    • Change from baseline in CHQ-PF-50 Psychological Summary Score at 12, 24, and
    36 months
    • Change from baseline in CHAQ Disability Index Score at 12, 24, and 36 months
    • Change from baseline WBFPRS at 12, 24, and 36 months
    • Change from baseline in growth velocity, determined by calculating age-adjusted Z-scores for height, weight, and BMI, at 12, 24 and 36 months
    • Serum concentration of denosumab at 1, 10, and 30 days, and 3, 6, 12, and 18 months
    E.5.2.1Timepoint(s) of evaluation of this end point
    See list above
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA7
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Australia
    Belgium
    Brazil
    Bulgaria
    Canada
    Colombia
    Czech Republic
    Estonia
    France
    Germany
    Greece
    India
    Italy
    Korea, Democratic People's Republic of
    Korea, Republic of
    Mexico
    New Zealand
    Peru
    Poland
    Russian Federation
    Spain
    Switzerland
    Turkey
    Ukraine
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    End of study: last subject last visit date
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years5
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years5
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 150
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) Yes
    F.1.1.5.1Number of subjects for this age range: 81
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 69
    F.1.2Adults (18-64 years) No
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state2
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 18
    F.4.2.2In the whole clinical trial 150
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2016-12-22
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-01-09
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2023-12-14
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 14:20:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA